James A Schoeneck bought $119k of KYNB
director at FIBROGEN INC. 23,567 shares at an average of $5.07, traded Jun 30, 2025, filed Jul 2, 2025.
Score components
- +15RoleDirector
- +10Trade size$119k at market
- +10Relative to holdingsHoldings up 146%
- +18Price context3% above the 52-week low; 73% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +31.2%, 3m +129.0%, 6m +67.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-019067, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2025 | POpen-market purchase Common Stockindirect: By Trust | +23,567 | $5.07 | $119k | 39,666 | Jul 2, 2025 |
Related signals
Other insiders at FIBROGEN INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | KYNBbuy FIBROGEN INC | Thane Wettig CEO | $20k 2,800 shares | +11% | |
| 36Weak | KYNBbuy FIBROGEN INC | Thane Wettig CEO | $20k 2,800 shares | +11% | |
| 42Moderate | KYNBbuy FIBROGEN INC | Thane Wettig CEO | $34k 3,700 shares | +17% | |
| 46Moderate | FIBROGEN INC | Thane Wettig CEO | $51k 145,000 shares | +36% | |
| 43Moderate | FIBROGEN INC | James A Schoeneck director | $105k 300,000 shares | +407% | |
| 34Weak | KYNBbuy FIBROGEN INC | Deyaa Adib Chief Medical Officer | $26k 22,123 shares | +37% | |
| 46Moderate | KYNBbuy FIBROGEN INC | Thane Wettig CEO | $95k 50,000 shares | +12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.